Teva turns the last corner in the CGRP migraine drug race with its 2nd round of promising PhIII data
Teva has brought in its second successful Phase III study of its CGRP migraine drug fremanezumab (TEV-48125), racking up a fresh slate of promising data across all endpoints that will soon be packaged and delivered into the hands of regulators.
Teva recruited a heavily afflicted group of patients for this episodic study with a mean number of 9.1 migraine days per month going in. Their $TEVA core data boils down to this: a 1.5-day advantage in reduced migraine days for the drug arm, putting it in the mix of around 2 days improvement across a full slate of CGRP rivals tested in a wide variety of mid- and late-stage studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
